Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine for rituximab-refractory indolent B‑cell lymphoma
CTR20131462Phase 2Active
- Sponsor
- Hangzhou Rongli Pharmaceutical Technology
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in low-grade B-cell lymphoma, sponsored by Hangzhou Rongli Pharmaceutical Technology. Primary endpoint: Overall response rate at end of 8 cycles. Started Nov 2013; status: active.
02
Drugs
bendamustine
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on CTR20131462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131462.